Table 1 Main clinical trials of active surveillance in patients with low-risk papillary thyroid carcinomas
Cohort (year) | n | Median follow-up (months) | Tumor growth ≥ 3 mm (% patients) | Lymph node metastasis (% patients) | Distant metastases (% patients) | Deaths (% patients) |
|---|---|---|---|---|---|---|
Sugitani et al. (2010) [19] | 230 | 5 | 7 | 1 | 0 | 0 |
Ito et al. (2014) [18] | 1235 | 120 | 8 | 3.8 | 0 | 0 |
Oda et al. (2016) [29] | 1179 | 36 | 2.3 | 0.5 | 0 | 0 |
Kwon et al. (2017) [30] | 192 | 30 | 14 | 0.5 | 0 | 0 |
Tuttle et al. (2017) [21] | 291 | 25 | 3.8 | 0 | 0 | 0 |
Kim et al. (2018) [31] | 126 | 26 | 5.6 | 0.8 | 0 | 0 |
Sakai et al. (2018) [20] | 61 | 88.8 | 7 | 3 | 0 | 0 |
Oh et al. (2018) [32] | 370 | 32.5 | 6.4 | 1.4 | 0 | 0 |
Smulever & Pitoia (2019) [22] | 34 | 42 | 17 | 0 | 0 | 0 |
Smulever & Pitoia (2020) [25] | 41 | 37 | 14.6 | 4.8 | 0 | 0 |
Molinaro et al. (2019) [33] | 93 | 19 | 2.1 | 1 | 0 | 0 |
Campopiano et al. (2021) [34] (2021) [34] | 109 | 31 | 4.5 | 2.7 | 0 | 0 |
MaeSTro (2022) [35] | 755 | 41.4 | 5.4 | 1.3 | 0 | 0 |